UR9 Stock Overview
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for UR9 from our risk checks.
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$8.76 |
52 Week High | AU$12.80 |
52 Week Low | AU$7.90 |
Beta | 0.74 |
1 Month Change | 7.62% |
3 Month Change | -11.75% |
1 Year Change | -25.94% |
3 Year Change | -51.34% |
5 Year Change | -49.29% |
Change since IPO | 68.42% |
Recent News & Updates
Recent updates
Shareholder Returns
UR9 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 1.8% | 1.0% | 1.8% |
1Y | -25.9% | 33.7% | 5.7% |
Return vs Industry: UR9 underperformed the German Biotechs industry which returned 34.7% over the past year.
Return vs Market: UR9 underperformed the German Market which returned 7% over the past year.
Price Volatility
UR9 volatility | |
---|---|
UR9 Average Weekly Movement | 6.3% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 9.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UR9 has not had significant price volatility in the past 3 months.
Volatility Over Time: UR9's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | n/a | Philippe Wolgen | https://www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
UR9 fundamental statistics | |
---|---|
Market cap | €434.82m |
Earnings (TTM) | €18.21m |
Revenue (TTM) | €49.39m |
23.9x
P/E Ratio8.8x
P/S RatioIs UR9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UR9 income statement (TTM) | |
---|---|
Revenue | AU$81.76m |
Cost of Revenue | AU$6.70m |
Gross Profit | AU$75.06m |
Other Expenses | AU$44.90m |
Earnings | AU$30.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.60 |
Gross Margin | 91.80% |
Net Profit Margin | 36.88% |
Debt/Equity Ratio | 0% |
How did UR9 perform over the long term?
See historical performance and comparison